Gut-On-A-Chip Market Global Report 2026

The gut-on-a-chip market size has grown rapidly in recent years. It will grow from $0.77 billion in 2025 to $0.87 billion in 2026 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to advancement in microfluidic engineering technologies, increasing research in human cell culture systems, growing demand for alternative animal testing methods, early adoption of organ-on-chip prototypes in academia, rising investment in biotechnology research infrastructure.

The gut-on-a-chip market size is expected to see rapid growth in the next few years. It will grow to $1.38 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to expansion of personalized medicine and precision drug testing, increasing pharmaceutical reliance on in-vitro modeling systems, growth in microbiome research and gut health studies, development of multi-organ integrated chip platforms, rising regulatory support for alternative testing technologies. Major trends in the forecast period include microfluidic gut simulation platforms enabling real-time intestinal physiology analysis, organ-on-chip integration for personalized drug response testing, microbiome interaction modeling using advanced gut-on-chip systems, high-throughput toxicity screening using microengineered intestinal models, stem cell based intestinal tissue replication for disease modeling and regenerative research.

The increasing incidence of gastrointestinal diseases is anticipated to drive the expansion of the gut-on-a-chip market in the coming years. Gastrointestinal diseases are disorders that affect the digestive system, including the stomach, intestines, colon, and rectum, often resulting in chronic inflammation, impaired digestion, and serious intestinal complications. The growing prevalence of these diseases is largely attributed to unhealthy eating habits and the increasing intake of processed food products that adversely impact digestive health. Gut-on-a-chip technology supports gastrointestinal disease research by replicating human intestinal functions and disease conditions, enabling researchers to investigate disease mechanisms, evaluate drug responses, and develop new therapeutic approaches. For instance, in January 2024, according to the American Cancer Society, a US-based nonprofit cancer organization, colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States, with around 53,010 projected deaths in 2024, compared to an estimated 52,550 deaths in the previous year. Therefore, the increasing incidence of gastrointestinal diseases is driving the growth of the gut-on-a-chip market.

Leading companies operating in the gut-on-a-chip market are focusing on developing advanced solutions, such as low-drug-absorbing rigid microfluidic chips, to improve predictive accuracy in absorption, distribution, metabolism, excretion, and toxicity studies. Low-drug-absorbing rigid microfluidic chips refer to advanced organ-on-chip devices manufactured using specialized plastic materials that minimize compound loss during experiments while maintaining controlled fluid flow and physiologically relevant cellular environments. For example, in September 2024, Emulate Inc., a US-based biotechnology company specializing in organ-on-a-chip platforms, human tissue models, and microfluidic research technologies, launched the Chip-R1 Rigid Chip for advanced organ-on-chip applications. The platform features low-drug-absorbing plastic construction, improved vascular channel design for physiologically relevant shear stress, and enhanced compatibility for absorption, distribution, metabolism, excretion, and toxicity testing applications in human-relevant tissue models.

In September 2023, CN Bio Innovations Ltd., a UK-based developer of organ-on-a-chip technologies, entered into a partnership with LifeNet Health LifeSciences to obtain validated primary human cells. Through this collaboration, CN Bio sought to enhance its organ-on-a-chip research capabilities by incorporating validated human cells into its PhysioMimix organ-on-a-chip platforms, improving applications in drug discovery and disease modeling. LifeNet Health LifeSciences is a US-based supplier of human tissue products, primary cells, and research biospecimens for biomedical research.

Major companies operating in the gut-on-a-chip market report are Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk Onderzoek (TNO), Micronit Microtechnologies B.V., Emulate Inc., CN Bio Innovations Limited, ibidi GmbH, BiomimX S.r.l., TissUse GmbH, MIMETAS B.V., Fluigent S.A., AIM Biotech Pte. Ltd., 4Dcell SAS, Hesperos Inc., Bi/ond Solutions B.V., SynVivo Inc., NETRI SAS, BEOnChip S.L., Dynamic42 GmbH, React4Life S.r.l., Kirkstall Ltd., AlveoliX AG, Nortis Inc., AxoSim Inc., InSphero AG, Altis Biosystems Inc., Organovo Holdings Inc.

North America was the dominating region in the gut-on-a-chip market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the gut-on-a-chip market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gut-on-a-chip market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.